安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAR 安飞士

已收盘 03-30 16:00:00 EDT

135.56

-12.89

-8.68%

盘后135.45

-0.11-0.08%

18:05 EDT

最高146.08	最低131.08	成交量224.10万
今开138.67	昨收148.45	日振幅10.10%
总市值47.71亿	流通市值20.02亿	总股本3,520万
成交额3.10亿	换手率15.17%	流通股本1,477万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":135.56,"timestamp":1774900800000,"preClose":148.45,"halted":0,"volume":2241024,"hourTrading":{"tag":"盘后","latestPrice":135.45,"preClose":135.56,"latestTime":"18:05 EDT","volume":54887,"amount":7440183.3202,"timestamp":1774908321617,"change":-0.11,"changeRate":-0.000811,"amplitude":0.000811},"delay":0,"changeRate":-0.08683058268777358,"floatShares":14770456,"shares":35196992,"eps":-25.25568,"marketStatus":"已收盘","change":-12.89,"latestTime":"03-30 16:00:00 EDT","open":138.67,"high":146.08,"low":131.08,"amount":309937944.37632,"amplitude":0.101044,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-25.25568,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774944000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":148.45,"preHourTrading":{"tag":"盘前","latestPrice":138.61,"preClose":148.45,"latestTime":"09:28 EDT","volume":11651,"amount":1589931.92763,"timestamp":1774877295421,"change":-9.84,"changeRate":-0.066285,"amplitude":0.099378},"postHourTrading":{"tag":"盘后","latestPrice":135.45,"preClose":135.56,"latestTime":"18:05 EDT","volume":54887,"amount":7440183.3202,"timestamp":1774908321617,"change":-0.11,"changeRate":-0.000811,"amplitude":0.000811},"volumeRatio":1.396278,"impliedVol":0.8418,"impliedVolPercentile":0.9124},"requestUrl":"/m/hq/s/CAR","defaultTab":"news","newsList":[{"id":"2620225813","title":"吉利德科学(GILD.US)CD19/CD20 CAR-T细胞疗法启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225813","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620225813?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:12","pubTimestamp":1773925932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月18日，美国临床试验收录网站显示，吉利德科学旗下公司Kite Pharma启动了KITE-753的首个III期临床试验。KITE-753是一款靶向CD19和CD20的双顺反子自体CAR-T细胞疗法。研究的主要终点是第6个月实现完全缓解的患者比例和36个月内的无事件生存期。结果显示，剂量3队列，在14例未接受过CAR-T细胞疗法治疗的患者中，11例实现CR，CR率为79%;总人群，在20例未接受过CAR-T细胞疗法治疗的患者中，14例实现CR，CR率为70%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2089984988.USD","LU1571399168.USD","LU1674673691.USD","GILD","LU1037948897.HKD","SG9999015986.USD","LU0965508806.USD","LU0965509010.AUD","SG9999015978.USD","LU0823416689.USD","LU0965509101.SGD","LU1061106388.HKD","LU0889565916.HKD","BK4568","LU1066051498.USD","LU0289739699.SGD","BK4139","LU1585245621.USD","IE00B3T34201.USD","LU0109394709.USD","LU1839511570.USD","IE00B19Z3B42.SGD","SG9999015945.SGD","LU0122379950.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","SG9999015952.SGD","BK4588","LU0114720955.EUR","III","LU0058720904.USD","LU0234570918.USD","LU1066053197.SGD","IE0002270589.USD","LU1934455863.HKD","LU1037948541.HKD","IE00B19Z3581.USD","LU2112291526.USD","LU0882574055.USD","BK4583","LU1674673428.USD","LU0861579265.USD","LU0965509283.SGD","LU1430594728.SGD","IE00BKVL7J92.USD","CAR","BK4134","LU1023059063.AUD","BK4022","BK4532"],"gpt_icon":0},{"id":"2620324027","title":"买保险送“特药卡”被叫停！这地展开全面排查","url":"https://stock-news.laohu8.com/highlight/detail?id=2620324027","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620324027?lang=zh_cn&edition=full","pubTime":"2026-03-19 15:08","pubTimestamp":1773904080,"startTime":"0","endTime":"0","summary":"近日，湖北金融监管局向辖内各保险省级分公司下发《关于规范保险业务活动中以“特药卡”等形式给予投保人或被保险人合同外利益的提示函》，严禁违规向保险消费者赠送“特药卡”“CAR-T卡”等权益卡。但与保险产品中的特药责任通过保险合同明确保障责任不同，“特药卡”主要提供方为第三方机构，并不属于保险产品，消费者权益难以获得有效保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652258948&idx=2&sn=7b4943724cb43d5b34c2b25de7f713a7&chksm=8503afd15c59e1d8e5115c36ca3eafd692833d5817147d60229a8edaa9c09342596046008d99&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4022","CAR","BK4230"],"gpt_icon":0},{"id":"2618956896","title":"传奇生物CAR-T销售放量，盈利拐点将至下的喜与忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956896","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618956896?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:25","pubTimestamp":1773149131,"startTime":"0","endTime":"0","summary":"3月10日，传奇生物（NASDAQ:LEGN）发布了截至2025年12月31日的第四季度及全年财务业绩。这份成绩单不仅标志着公司核心产品CARVYKTI?（西达基奥仑赛）首次实现产品线盈利，也展现出国产CAR-T出海标杆从“烧钱扩张”向“自我造血”转型的关键一跃。财报显示，CARVYKTI?在2025年第四季度实现净销售额约5.55亿美元，全年销售额达18.87亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667731683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667731683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","LEGN","BK4505","BK4139","BK4585","BK4588","BK4230","BK4022"],"gpt_icon":0},{"id":"2616762809","title":"港股异动 | 科济药业-B(02171)再跌超8% TCE优异数据引发市场对自体CAR-T前景担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2616762809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616762809?lang=zh_cn&edition=full","pubTime":"2026-03-02 11:31","pubTimestamp":1772422318,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B再跌超8%，截至发稿，跌8.06%，报13港元，成交额1892.91万港元。该行指出，自体CAR-T凭借优异的疗效具备极大的吸引力，2025年全球销售额已接近60亿美元。近期TCE优异的数据引起市场对自体CAR-T前景的担忧，主要因为疗效接近的情况下自体CAR-T复杂的制备和使用过程，以及高昂的成本带来的价格劣势格外突出。in vivo CAR-T是解决以上问题极具潜力的方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4230","BK4588","CAR","VT","BK4585","VXUS","BK1161","BK1587","BK1574","BK4022","BK1585","02171"],"gpt_icon":0},{"id":"2614852749","title":"吉利德78亿美元全面收购Arcellx公司获得BCMA-CAR T疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2614852749","media":"药企市值评估","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614852749?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:46","pubTimestamp":1772196399,"startTime":"0","endTime":"0","summary":"近日，吉利德宣布以78亿美元估值全面收购其2022年就牵手合作的伙伴公司Arcellx，消息宣布当天Arcellx股价大涨近80%。以下文字写于2024年11月，标题《再论Arcellx公司的BCMA-CAR T疗法》我又仔细研读了Arcellx公司2023年年报，发现这个公司在技术上还是有一些新东西的。目前传奇生物是70亿美元市值出头，Arcellx甚至有追平的趋势。以下文字写于2023年11月，标题《Arcellx公司的BCMA-CART似乎数据不错，但是临床进展太滞后了》近日，","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227213733a4379541&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227213733a4379541&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4022","BK4588","BK4139","LEGN","CAR","BK4505","BK4230"],"gpt_icon":0},{"id":"1167701131","title":"BioNTech将于2026年3月10日公布2025年第四季度及全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1167701131","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167701131?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:50","pubTimestamp":1771933815,"startTime":"0","endTime":"0","summary":"德国美因茨，2026年2月24日——BioNTech SE将于2026年3月10日星期二发布其2025年第四季度及全年的财务业绩。同日，公司将于美国东部时间上午8:00举行电话会议和网络直播，面向投资者、财务分析师及公众讨论财务业绩并提供公司最新动态。BioNTech是一家全球性的新一代免疫疗法公司，致力于开发针对癌症及其他重大疾病的新型研究性疗法。更多信息请访问www.BioNTech.com。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CAR","BK4551","BK4548","BK4588","BNTX","BK4139","BK4568","BK4230","BK4535","BK4585"],"gpt_icon":0},{"id":"2613276531","title":"东方证券：自体CAR-T价格劣势格外突出 in vivo CAR-T是解决问题潜力方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2613276531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613276531?lang=zh_cn&edition=full","pubTime":"2026-02-24 11:47","pubTimestamp":1771904844,"startTime":"0","endTime":"0","summary":"in vivo CAR-T是解决以上问题极具潜力的方向，目前整体处于临床早期，初步数据已经验证疗效，安全性有望优于自体CAR-T，MNC已下场达成众多大额合作交易或收购，国内企业布局数量众多，未来有望达成多项交易。目前，临床阶段的in vivo CAR-T管线数量超过20款，整体进度处于早期阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1564","03958","BK0188","BK0028","BK0276","BK4022","BK1147","BK0183","600958","BK0012","CAR","BK4230"],"gpt_icon":0},{"id":"2613056764","title":"78 亿美元！吉利德收购 Arcellx 加码 CAR-T 赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2613056764","media":"药时空","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613056764?lang=zh_cn&edition=full","pubTime":"2026-02-24 08:15","pubTimestamp":1771892158,"startTime":"0","endTime":"0","summary":"当地时间 2026 年 2 月 23 日，全球生物制药巨头吉利德科学宣布，将以 78 亿美元隐含股权价值收购临床阶段生物技术公司 Arcellx，此次收购直指后者核心 CAR-T 管线 Anito-cel 与独创的 D-Domain 技术平台，成为吉利德在肿瘤免疫治疗领域的重要布局，也为多发性骨髓瘤治疗赛道注入新动能。交易已获双方董事会批准，预计 2026 年第二季度完成，吉利德目前已持有 Arcellx11.5% 流通股，将通过全资子公司要约收购剩余股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022408423997a6bfea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022408423997a6bfea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","IE00B7SZLL34.SGD","BK4583","IE00B19Z3581.USD","LU1066051498.USD","SG9999015945.SGD","LU0320765992.SGD","LU0058720904.USD","LU1037948897.HKD","BK4230","LU1037948541.HKD","BK4566","LU0234570918.USD","BK4578","SG9999015952.SGD","LU2468319806.SGD","LU1571399168.USD","LU0965509101.SGD","IE00BZ1G4Q59.USD","BK4585","IE0002270589.USD","IE00B3T34201.USD","LU0122379950.USD","LU1023059063.AUD","BK4022","LU0965509283.SGD","LU2089984988.USD","LU1839511570.USD","LU0882574055.USD","LU1674673428.USD","GILD","LU2324357040.USD","LU0823416689.USD","LU1674673691.USD","SG9999015986.USD","LU0965508806.USD","CAR","LU0889565916.HKD","LU0965509010.AUD","LU1061106388.HKD","LU1066053197.SGD","LU0289739699.SGD","LU1778281490.HKD","LU2112291526.USD","BK4588","IE00B19Z3B42.SGD","LU0109394709.USD","IE00BSNM7G36.USD","LU0114720955.EUR","SG9999015978.USD"],"gpt_icon":0},{"id":"1127638298","title":"异动解读 | 遭杰富瑞大幅下调目标价，安飞士盘中大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127638298","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127638298?lang=zh_cn&edition=full","pubTime":"2026-02-23 23:09","pubTimestamp":1771859341,"startTime":"0","endTime":"0","summary":"安飞士（CAR）今日盘中股价大跌5.05%，引发了市场关注。消息面上，华尔街知名投行杰富瑞（Jefferies）发布研究报告，将安飞士（Avis Budget Group Inc）的目标价从175美元大幅下调至112美元。分析师大幅调降目标价通常反映了对公司未来盈利前景或估值的担忧，这一负面评级调整直接影响了市场情绪，导致股价承压下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CAR"],"gpt_icon":0},{"id":"1163996277","title":"异动解读 | 季度财报不及预期，安飞士盘中大跌20.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163996277","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163996277?lang=zh_cn&edition=full","pubTime":"2026-02-19 23:20","pubTimestamp":1771514452,"startTime":"0","endTime":"0","summary":"安飞士（CAR）今日盘中股价大幅下跌20.65%，引起了市场的广泛关注。消息面上，该公司此前公布了令人失望的第四季度财报。财报显示，其季度销售额为26.6亿美元，低于华尔街预期的27.4亿美元，主要由于日均销售额和租赁天数双双下降。此外，公司调整后的息税折旧摊销前利润（EBITDA）仅为500万美元，远低于市场预期的1.458亿美元。报告期内净亏损达8.56亿美元，其中包含了5.18亿美元的美国电动汽车租赁车辆减值及其他相关费用。这份不及预期的季度业绩报告是导致安飞士股价在交易时段内大幅下挫的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CAR"],"gpt_icon":0},{"id":"1109942739","title":"异动解读 | 安飞士夜盘大跌10.97%，因Q4营收不及预期且电动汽车车队减值","url":"https://stock-news.laohu8.com/highlight/detail?id=1109942739","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109942739?lang=zh_cn&edition=full","pubTime":"2026-02-19 09:11","pubTimestamp":1771463479,"startTime":"0","endTime":"0","summary":"安飞士(CAR)今日夜盘股价大跌10.97%，引起了市场的广泛关注。消息面上，安飞士公布的第四季度财报显示，营收为27亿美元，低于分析师普遍预期的27.5亿美元。同时，该公司报告每股亏损21.25美元，该季度业绩受到与公司美国电动汽车车队相关的5.18亿美元减值支出的显著影响，因为安飞士缩短了这些资产的使用寿命。投资者对营收未达预期以及公司持续调整电动汽车战略感到担忧，导致股价在夜盘交易中大幅下跌。尽管面临挑战，公司管理层表示正在加强车队管理、强化资产负债表并提升客户体验，以推动可持续的盈利增长。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CAR"],"gpt_icon":0},{"id":"1103385064","title":"安飞士Q4营收27亿美元，不及市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1103385064","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103385064?lang=zh_cn&edition=full","pubTime":"2026-02-19 07:01","pubTimestamp":1771455682,"startTime":"0","endTime":"0","summary":"2月19日，安飞士盘后暴跌逾12%！该公司第四季度营收为27亿美元，低于分析师普遍预期的27.5亿美元。安飞士报告每股亏损21.25美元，较去年同期每股亏损55.66美元有所改善。消息公布后，这家租车公司的股价暴跌，投资者对营收未达预期以及持续调整电动汽车战略感到担忧。该公司第四季度调整后EBITDA仅为500万美元，而全年调整后EBITDA为7.48亿美元，年营收为117亿美元。安飞士本季度末流动资金约为8.18亿美元，另有21亿美元的车队融资能力。","market":"us","thumbnail":"https://static.tigerbbs.com/a94db4188d9d2f07ffcb272fc408277d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a94db4188d9d2f07ffcb272fc408277d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"安飞士Q4营收27亿美元，不及市场预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"gpt_icon":0},{"id":"2611952901","title":"科济药业-B(02171)与上海金工企业发展签署战略合作协议 投建金山CAR-T细胞治疗产品商业化生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2611952901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611952901?lang=zh_cn&edition=full","pubTime":"2026-02-13 08:07","pubTimestamp":1770941237,"startTime":"0","endTime":"0","summary":"在此背景下，提升符合国际标准的CAR-T细胞治疗产能成为支撑多个产品商业化落地及增强全球竞争力的核心举措。总体来看，此次合作彰显了本公司稳健的财务规划和对CAR-T细胞治疗产业生态系统的深度布局，也表明该项目高度契合国家及地方的生物医药产业政策，得到了政府层面的高度重视与大力支持。这项战略合作将助力本公司进一步巩固其在全球CAR-T细胞治疗领域的领先地位，同时为股东创造长远价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159830","BK1587","BK4230","02171","BK1161","BK1585","CAR","BK1574","BK4022"],"gpt_icon":0},{"id":"1124649550","title":"财报前瞻 ｜安飞士本季度营收预计增长0.98%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1124649550","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124649550?lang=zh_cn&edition=full","pubTime":"2026-02-11 10:45","pubTimestamp":1770777919,"startTime":"0","endTime":"0","summary":"- 上季度预告与实际：EBIT实际5.85亿美元、同比增长37.97%；EPS实际10.11美元、同比增长52.03%；营收实际35.19亿美元、同比增长1.12%. - 本季度预测：营收预计27.38亿美元、同比增长0.98%；EBIT预计0.88亿美元、同比增长239.64%；EPS预计-0.42美元、同比增长36.90%. 安飞士本季度预计营收增长0.98%，对应旅游与商务出行的淡旺季切换，需求呈现结构性的回落。从近期机构观点来看，市场整体偏谨慎，关注淡季盈利与EPS为负的压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜安飞士本季度营收预计增长0.98%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"gpt_icon":0},{"id":"1195423611","title":"CAR集团AI投资难消估值疑虑——市场评论","url":"https://stock-news.laohu8.com/highlight/detail?id=1195423611","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195423611?lang=zh_cn&edition=full","pubTime":"2026-02-10 07:10","pubTimestamp":1770678651,"startTime":"0","endTime":"0","summary":"CAR集团持续加码人工智能领域的投资，但这并未能消除麦格理集团对该技术潜在估值影响的担忧。尽管该投行的分析师认同这家汽车广告平台管理层的观点，即AI能力确实能加速短期产品开发并提升成本效益，但他们对此后的发展前景仍持谨慎态度。\n分析师在给客户的报告中指出，这家澳大利亚公司战略执行良好，短期投资应能支撑其中期增长。然而，外部AI服务商在多大程度上能复制其专业的分类广告能力存在不确定性，加之潜在股价催化因素尚不明确，这使得麦格理对估值发现过程保持警惕。\n麦格理将其目标股价下调27%至28.50澳元，并维持对该股的中性评级。该股在开盘前报26.91澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR.AU","BK4022","CAR","BK7002","BK4230","BK7503"],"gpt_icon":0},{"id":"2609660445","title":"安飞士盘中异动 下午盘股价大跌5.10%报116.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609660445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609660445?lang=zh_cn&edition=full","pubTime":"2026-02-06 02:48","pubTimestamp":1770317309,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日02时48分，安飞士股票出现波动，股价急速跳水5.10%。截至发稿，该股报116.62美元/股，成交量21.602万股，换手率0.61%，振幅4.13%。机构评级方面，在所有9家参与评级的机构中，22%的券商给予买入建议，56%的券商给予持有建议，22%的券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体跌幅为1.17%。安飞士致力于服务旅游业高端的商务及休闲细分市场，百捷特则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020602482997a51378&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020602482997a51378&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2608335603","title":"2025年In Vivo CAR-T竞争格局及BD情况：MNC重金布局，中国药企多点开花迎突破！","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335603","media":"摩熵医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608335603?lang=zh_cn&edition=full","pubTime":"2026-02-03 11:43","pubTimestamp":1770090193,"startTime":"0","endTime":"0","summary":"2025年，这一前沿领域迎来了里程碑式的进展——虹信生物基于mRNA-LNP技术的In Vivo CAR-T候选药物HN2301首次在人体上验证了该技术路径的可行性。这不仅为自身免疫疾病的治疗开辟了新路径，也正式宣告In Vivo CAR-T从实验室加速走向临床应用。据不完全统计，仅2025年一年，全球围绕In Vivo CAR-T的重磅交易金额已超过65亿美元。2026年in vivo CAR-T赛道将持续火热，并且该趋势很有可能有增无减。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1066053197.SGD","LU0795875086.SGD","BK4550","IE00BFXG1179.USD","LU1244550494.USD","IE00BZ1G4Q59.USD","IE00BLSP4239.USD","LU2430703178.SGD","IE0002141913.USD","LU1066051811.HKD","LU0345769128.USD","BK4534","IE00BVYPNW00.USD","LU1267930813.SGD","JNJ","IE00BVYPNV92.GBP","LU0203345920.USD","LU1732799900.SGD","CAR","IE00B2B36J28.USD","LU0320765646.SGD","BK4504","BK4007","BK4568","BK4533","IE00B19Z3581.USD","LU1074936037.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU1674673691.USD","IE0009355771.USD","LU1244550577.SGD","BK4559","LU1732800096.USD","LU0792757196.USD","LU0122379950.USD","SG9999002232.USD","LU0234572021.USD","LU1244550221.USD","LU2129689605.HKD","LU2430703251.USD","LU2592432038.USD","LU2602419157.SGD","IE00BBT3K403.USD","LU0058720904.USD","LU2505996509.AUD","LU0070217475.USD","LU1059921491.USD","LU1914381329.SGD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2605442845","title":"晶泰科技(02228)赋能莱芒生物取得细胞疗法重大成果，以1‰剂量CAR-T实现多位系统性红斑狼疮完全缓解出院","url":"https://stock-news.laohu8.com/highlight/detail?id=2605442845","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605442845?lang=zh_cn&edition=full","pubTime":"2026-01-23 09:54","pubTimestamp":1769133255,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，晶泰科技孵化企业莱芒生物在第 44 届摩根大通医疗健康年会发表演讲，并向全球投资者展示了其极低剂量 CAR-T 疗法的研究者发起临床最新成果。血液瘤与自身免疫疾病临床双重突破在晶泰科技的助力下，莱芒生物开发的代谢增强型 CD19 CAR-T疗法，在自免性疾病和血液瘤领域展现出突破性治疗潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4022","BK1617","02228","BK1141","CAR","BK4230"],"gpt_icon":0},{"id":"2605446971","title":"终于有国产CAR-T企业快要扭亏了！传奇生物预计今年实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2605446971","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605446971?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:08","pubTimestamp":1769072934,"startTime":"0","endTime":"0","summary":"在绝大多数国产CAR-T企业苦于商业化挣扎之际，率先出海的传奇生物（LEGN.NS）业绩快要“上岸”了。传奇生物的CAR-T药物合作方强生于当地时间1月21日公布的财报显示，Carvykti（西达基奥仑赛）在2025年实现收入18.88亿美元，较上年同期（9.63亿美元）增长95.9%。西达基奥仑赛是一款用于治疗复发或难治性多发性骨髓瘤的细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627442037.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627442037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4505","BK4588","LEGN","BK4022","CAR","BK4230","BK4139"],"gpt_icon":0},{"id":"2605646854","title":"强生今年营收有望破千亿美元：去年净利增九成，CAR-T收入增95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605646854","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605646854?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:14","pubTimestamp":1769066066,"startTime":"0","endTime":"0","summary":"跨国药企强生交出了营收净利双增的业绩，来自中国的CAR-T疗法销售表现亮眼。当地时间1月21日，美国强生公司公布2025年四季报以及全年财报。2025年第四季度收入245.64亿美元，同比增长9.1%，净利润51.16亿美元，同比增长49.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627319570.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627319570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["JNJ","CAR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":0.486},{"period":"1month","weight":0.598},{"period":"3month","weight":0.1252},{"period":"6month","weight":-0.0795},{"period":"1year","weight":1.0018},{"period":"ytd","weight":0.1569}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.是一家全球领先的车辆租赁和汽车共享服务提供商，通过Avis、Budget和Zipcar运营着业内最受认可的三个品牌。该公司是北美、欧洲、澳大利亚、新西兰和某些地区领先的车辆租赁运营商。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.011725},{"month":2,"riseRate":0.5625,"avgChangeRate":0.031733},{"month":3,"riseRate":0.625,"avgChangeRate":0.067162},{"month":4,"riseRate":0.666667,"avgChangeRate":0.02598},{"month":5,"riseRate":0.466667,"avgChangeRate":0.01481},{"month":6,"riseRate":0.533333,"avgChangeRate":0.033428},{"month":7,"riseRate":0.6,"avgChangeRate":0.040059},{"month":8,"riseRate":0.4,"avgChangeRate":-0.00977},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.027276},{"month":10,"riseRate":0.666667,"avgChangeRate":0.119671},{"month":11,"riseRate":0.666667,"avgChangeRate":0.07647},{"month":12,"riseRate":0.4,"avgChangeRate":-0.047503}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}